Evaluation of Medication Use in Patients with Gastroesophageal Reflux Disease (GERD) in the Inpatient Unit at a Hospital in Cimahi
Abstract
Gastroesophageal Reflux Disease (GERD) is a pathological condition characterized by the regurgitation of gastric contents into the esophagus, resulting in symptoms affecting both the esophagus and extra-esophageal regions. The aim of this study is to ascertain the usage pattern and rationality of GERD medication consumption. This study utilizes an observational approach with a descriptive cross-sectional design. The data collection was performed retrospectively by examining the treatment histories of GERD patients documented in the medical records at the Inpatient Installation of Dustira Hospital from January to June 2023. The sample comprised 200 persons who met the inclusion criteria. Research indicated that individuals with GERD were predominantly female, comprising 73.5%, while males constituted approximately 26.5%. The predominant age range was 18-45 years, comprising 63.5%, followed by 46-59 years at 23.5%. 61 patients received a combination of omeprazole and sucralfate as the predominant medication. The analysis showed that 100% of patients utilized the medication with the appropriate indication, 97.5% with accurate drug selection, 100% with precise dosage, 100% with the right method of administration, and 100% with the appropriate administration interval
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 61 participants or records.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.